Study outcomes
migraine
MIGRAINE, SECONDARY
The primary endpoint for efficacy was the change from baseline in MMDs over the 12-week placebo-controlled period (Weeks 1–12). Key secondary endpoints, listed in the testing hierarchy order, were the change from baseline in MMDs with use of AHM (Weeks 1–12), proportion of patients with ≥ 50% reduction from baseline in MMDs (migraine responder rate [MRR]; Weeks 1–12), migraine rate on the day after dosing (Day 1), proportion of patients with ≥ 75% reduction from baseline in MMDs (Weeks 1–4), change from baseline in the number of MHDs (Weeks 1–12), and proportion of patients with ≥ 75% reduction from baseline in MMDs (Weeks 1–12). Additional prespecified secondary and exploratory endpoints and the safety endpoints are summarized in Supplemental Table 